CD276 and neoplasm: Our group developed a flowcytometry based detection assay for tumor derived CD276+CECs, differentiating CECs from non-endothelial cells (i.e., pericytes) and between normal and malignant vasculature, which enables to distinguish a subpopulation of CECs coming from malignant vasculature in patients with advanced malignancies.